Versant Venture Management, LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001560009 · Show all filings

Period: Q2 2024 (← Previous) (Next →)

Filing Date: Aug 7, 2024

Total Value: $77.3M (100.0% shares, 0.0% debt)

Holdings (8)

CRSP CRISPR Therapeutics AG 34.8%

Value $26.93M Shares 498,558 Est. Cost $40.26 Unrealized +43.7%

CTNM Contineum Therapeutics, Inc. 20.9%

Value $16.17M Shares 918,163 Est. Cost $16.10 Unrealized 0.0%

SKYE Skye Bioscience, Inc. 20.8%

Value $16.08M Shares 2,007,704 Est. Cost $7.75 Unrealized +52.8%

— Repare Therapeutics, Inc. 11.3%

Value $8.734M Shares 2,646,657 Est. Cost $10.58 Unrealized —

— Adverum Biotechnologies, Inc. 4.5%

Value $3.477M Shares 506,821 Est. Cost $9646.10 Unrealized —

— Passage Bio, Inc. 4.1%

Value $3.198M Shares 4,026,417 Est. Cost $17.48 Unrealized —

— Gritstone Oncology, Inc. 2.8%

Value $2.2M Shares 3,561,150 Est. Cost $7767.86 Unrealized —

— Aligos Therapeutics, Inc. 0.7%

Value $510K Shares 1,457,937 Est. Cost $27.65 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
CRSP	CRISPR Therapeutics AG	498,558	$26.93M	34.8%	$40.26	+43.7%	Common Shares	H17182108
CTNM	Contineum Therapeutics, Inc.	918,163	$16.17M	20.9%	$16.10	0.0%	Common Stock	21217B100
SKYE	Skye Bioscience, Inc.	2,007,704	$16.08M	20.8%	$7.75	+52.8%	Common Stock	83086J200
—	Repare Therapeutics, Inc.	2,646,657	$8.734M	11.3%	$10.58	—	Common Stock	760273102
—	Adverum Biotechnologies, Inc.	506,821	$3.477M	4.5%	$9646.10	—	Common Stock	00773U108
—	Passage Bio, Inc.	4,026,417	$3.198M	4.1%	$17.48	—	Common Stock	702712100
—	Gritstone Oncology, Inc.	3,561,150	$2.2M	2.8%	$7767.86	—	Common Stock	39868T105
—	Aligos Therapeutics, Inc.	1,457,937	$510K	0.7%	$27.65	—	Common Stock	01626L105